Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.45 |
| ▸ | F7 | P08709 | 6/20 | 0.42 |
| ▸ | F3 | P13726 | 6/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PPID | Q08752 | 1/20 | 0.36 |
| ▸ | PPIG | Q13427 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613436 | 0.85 | MEN1 (0.46) | RIPK1LMNA | |
| SCHEMBL2916946 | 0.83 | F7 (0.45) | F7F3F2F10F11 | |
| SCHEMBL17093004 | 0.80 | RIPK1 (0.51) | RIPK1HSP90AA1HSP90AB1 | |
| SCHEMBL27199645 | 0.79 | RIPK1 (0.46) | RIPK1HSP90AA1HSP90AB1PREPFAP | |
| SCHEMBL29751202 | 0.79 | RIPK1 (0.46) | RIPK1HSP90AA1HSP90AB1PREPFAP | |
| SCHEMBL6310168 | 0.76 | HSP90AA1 (0.61) | RIPK1HSP90AA1HSP90AB1 | |
| SCHEMBL16964986 | 0.76 | RIPK1 (0.48) | RIPK1F2HSP90AA1HSP90AB1 | |
| SCHEMBL22165570 | 0.75 | RIPK1 (0.47) | RIPK1HSP90AA1HSP90AB1 | |
| SCHEMBL5531271 | 0.74 | SLC6A4 (0.38) | RIPK1F7F3LMNA | |
| SCHEMBL28946650 | 0.74 | RIPK1 (0.46) | RIPK1HSP90AA1HSP90AB1PPIDPPIG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856096-B1 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7622585-B2 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1856096-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Bristol-Myers Squibb Company (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| WO-2006076246-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | TFPI, SERPINC1, SERPINE1 | RIPK1 3020/4885F7 35/4885F3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.